scholarly journals STRONTIUM RANELATE DECREASES VERTEBRAL FRACTURE RISK WHATEVER THE LEVEL OF PRETREATMENT BONE TURNOVER MARKERS

2007 ◽  
Vol 10 (2) ◽  
pp. 27
Author(s):  
J COLLETTE ◽  
J Y REGINSTER ◽  
O BRUYÈRE ◽  
C ROUX ◽  
R LORENC ◽  
...  
Keyword(s):  
Vertebral Fracture ◽  
Bone Turnover ◽  
Fracture Risk ◽  
Strontium Ranelate ◽  
Bone Turnover Markers ◽  
Vertebral Fracture Risk ◽  
Turnover Markers

Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk

2003 ◽  
Vol 19 (3) ◽  
pp. 394-401 ◽  
Author(s):  
Somnath Sarkar ◽  
Jean-Yves Reginster ◽  
Gerald G Crans ◽  
Adolfo Diez-Perez ◽  
Karen V Pinette ◽  
...  
Keyword(s):  
Vertebral Fracture ◽  
Bone Turnover ◽  
Fracture Risk ◽  
Biochemical Markers ◽  
Vertebral Fracture Risk ◽  
Markers Of Bone Turnover

scholarly journals Antiresorptive Therapy and the Bone Turnover Markers—Assessed Fracture Risk in Postmenopausal Women

2020 ◽  
Author(s):  
Ljiljana Smilic ◽  
Tanja Smilic ◽  
Aleksandar N. Jovanovic ◽  
Snezana R. Markovic - Jovanovic ◽  
Zlatica Mirkovic ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Fracture Risk ◽  
Postmenopausal Women ◽  
Bone Turnover Markers ◽  
Bone Markers ◽  
Antiresorptive Therapy ◽  
Mineral Density ◽  
Metabolic Markers ◽  
Increased Risk ◽  
Turnover Markers

Abstract Purpose/Introduction: The aim of this study was to determine relationship of the bone markers levels with the fracture risk and treatment monitoring in patients with osteoporosis. Bone markers may point out to on specific aspects of bone quality, detecting changes of bone mineral density, thus providing prognostic perspective and accounting for a substantial proportion of fracture risk reduction.Methods: The case-control study comprised data from 55 patients undergoing evaluation for osteoporosis at Medicus Universalis Polyclinic in Krusevac. Densitometric findings, P1NP, CTX and osteocalcin levels were determined in all patients twice – at the first assessment and 6 months after. While 30 patients took no medical therapy, 25 of them were treated with ibandronate. Results: No convincing difference in densitometric measurements between patients with and without prevalent fractures were noted, while mean osteocalcin and P1NP levels were significantly lower (p<0.05) in osteoporotic patients who suffered fractures. A significant correlation between those bone turnover markers and T-score was established, especially in the second measurement and in patients treated with ibandronate.Conclusion: In postmenopausal women and individuals with low BMD, the presence of increased bone turnover markers suggests an increased risk of fractures. Furthermore, these metabolic markers are useful in the monitoring of patients receiving antiresorptive therapy, wherein fast decline of their levels indicate favorable course. Their determination after 6 months offers the remarkable advantage in assessing the effectiveness of medical treatment comparing to 12–24 months required to document changes by BMD.

Sign in / Sign up

Export Citation Format

Share Document